Technology Transfer in Cell and Gene Therapy: Challenges and Opportunities for the Future

Current developments in technology transfer to a Contract Development and Manufacturing Organization (CDMO)

In an exclusive interview with EPR editor Caroline Peachey at Terrapin’s Advanced Therapies conference in London on 19 March, Roberto Formisano, Process Transfer Senior Manager at AGC Biologics, delves into the challenges associated with technology transfer. He provides insights on the nuances of technology transfer, both from development to GMP manufacturing and from a customer to a contract development and manufacturing organization (CDMO).

During the interview, Roberto highlights one of the key challenges facing the industry: the critical timelines that are integral to the process of technology transfer. Balancing the number of batches that need to be manufactured to ensure sufficient quality data while adhering to these timelines poses a significant challenge in the industry.

Furthermore, Roberto shares his predictions on technology and manufacturing trends that are expected to shape the cell and gene therapy industry by 2024. His insights provide valuable perspectives on the future direction of the industry. Overall, this interview sheds light on the complexities of technology transfer and offers valuable insights into the industry’s challenges and opportunities.

Leave a Reply